SpineSmith Acquires Rights to Tissue Genesis’ Stem Cell Isolating Technology for Diagnosis and Treatment of the Human Spine
Adipose tissue has proven to be an abundant source of adult stem cells with the potential to form new bone and regenerate tissue.
Austin, Texas (PRWEB) November 8, 2007 -- SpineSmith Partners, LP acquired rights in spine for Tissue Genesis, Inc.’s adipose (fat) tissue derived cell technology. Tissue Genesis’ TGI 100™ cell isolation kits and TGI 1000™ automated cell isolation systems will rapidly process autologous (patient-derived) adipose tissue and isolate large quantities of regenerative cells, which can be utilized to treat a number of spine related diseases. Adipose tissue has proven to be an abundant source of adult stem cells with the potential to form new bone and regenerate tissue. The Tissue Genesis technologies are currently being researched and developed to treat a number of spinal pathologies.
Under the terms of the agreement, SpineSmith Partners has licensed the rights to all of Tissue Genesis’s patents and technologies for use in the diagnosis and treatment of the human spine. The stem cell therapy will be delivered to the patient via osteobiologic carriers currently on the market and under development. The ability to harvest and implant autologous cells in the operating room at the point-of-care should provide benefits to the surgeon, the patient and the healthcare system.
“This exciting new relationship with SpineSmith allows Tissue Genesis to move our therapeutic cell technologies into orthopedic markets,” said Anton C Krucky, President and CEO of Tissue Genesis. “SpineSmith’s extensive expertise with bone marrow stem cells, in both cell isolation and medical insurance reimbursement, provides a clear avenue of advancement of our adipose (fat) derived stem cells into this important market.”
“SpineSmith has been involved in the treatment of spine injuries for over two years, having provided bone marrow derived, autologous stem cells (the patient’s own) to over three thousand patients,” said Kevin Dunworth, founder of SpineSmith. “We believe stem cells to be the next frontier in spine surgery and the Tissue Genesis cell isolation system rapidly processes a small quantity of a patient’s own fat tissue to produce large quantities of cells, including adult stem cells and microvascular cells.”
About SpineSmith Partners, LP
SpineSmith Partners, LP (www.spinesmithusa.com) designs, develops and markets implants and biologics for surgical fixation, correction and tissue regeneration of the spine. SpineSmith takes a different approach from other companies, utilizing a collaborative approach between scientists, engineers and spine surgeons. This approach results in the development of truly innovative biological and hardware technologies for use in the treatment of patients with spinal disorders. SpineSmith’s unique, think-tank approach gives spine surgeons the ability to directly impact the direction of its product portfolio, ensuring applicability and achieving the highest standards of patient care.
About Tissue Genesis, Inc.
Tissue Genesis, Inc.(www.tissuegenesis.com) is a Qualified High Technology Business (QHTB) in Honolulu, Hawaii that is seeking to develop innovative tissue engineering solutions and technology to address a range of therapeutic areas including vascular, cardiovascular, orthopedic and veterinarian. The company expects its technology to isolate autologous adipose derived cells in less than two hours for delivery of the cells at point-of-care for immediate patient needs.
Contact Information:
Keri Kimler
512 206 0770
info @ spinesmithusa.com
8140 North Mopac, Bldg II, Suite 120
Austin, Tx 78759
www.spinesmithusa.com
phone 512 206 0770
fax 512 637 6750
# # #
|
